A share price of Vir Biotechnology Inc [VIR] is currently trading at $11.20, up 6.36%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VIR shares have gain 6.67% over the last week, with a monthly amount glided 51.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $9 from $23. Previously, BofA Securities downgraded its rating to Neutral on September 08, 2023, and dropped its price target to $14. On March 06, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $34 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $30 on January 27, 2023. SVB Leerink started tracking with a Outperform rating for this stock on September 14, 2022, and assigned it a price target of $40. In a note dated September 09, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $15 on this stock.
Vir Biotechnology Inc experienced fluctuations in its stock price throughout the past year between $6.56 and $14.45. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $11.20 at the most recent close of the market. An investor can expect a potential return of 114.29% based on the average VIR price forecast.
Analyzing the VIR fundamentals
Trailing Twelve Months sales for Vir Biotechnology Inc [NASDAQ:VIR] were 78.62M which represents -9.81% decline. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -6.58%, Pretax Profit Margin comes in at -6.86%, and Net Profit Margin reading is -6.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.37 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.54 points at the first support level, and at 9.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.63, and for the 2nd resistance point, it is at 12.05.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vir Biotechnology Inc [NASDAQ:VIR] is 8.94. As well, the Quick Ratio is 8.94, while the Cash Ratio is 2.2. Considering the valuation of this stock, the price to sales ratio is 19.62, the price to book ratio is 1.23.
Transactions by insiders
Recent insider trading involved SATO VICKI L, Director, that happened on Jan 08 ’25 when 10960.0 shares were sold. Director, VICKI LEE SATO completed a deal on Jan 08 ’25 to buy 43840.0 shares. Meanwhile, EVP and General Counsel de Verneuil Vanina sold 76.0 shares on Dec 02 ’24.
